26 Feb 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
20 Aug 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
20 Aug 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mr. Herve Affagard CEO | OTC PINK Exchange | AU000000OEC2 ISIN |
France Country | 54 Employees | - Last Dividend | 1 Nov 2010 Last Split | 4 Dec 1991 IPO Date |
Orbital Corporation Limited specializes in providing integrated propulsion systems and flight critical components tailored primarily for tactical unmanned aerial vehicles (UAVs), with its operational footprint spanning Australia and the United States. Initially established as Orbital Engine Corporation Limited, the organization underwent a rebranding in October 2004 to its current name, reflecting a broader scope in its offerings. Founded in 1988 and with its headquarters situated in Balcatta, Australia, Orbital Corporation Limited emerges as a pivotal entity in the aerospace sector, offering comprehensive solutions from design to support for its global clientele.